

**FOR IMMEDIATE RELEASE**

**TSX-V: PGA**

## **PACGEN APPOINTS NEW SCIENTIFIC ADVISORY BOARD MEMBERS**

**Vancouver, BC, Canada (February 12, 2007)** – Pacgen Biopharmaceuticals Corporation (“Pacgen”) (TSX-V: PGA) announces the appointment of Dr. J. Mark FitzGerald, Dr. William Nauseef, and Dr. Brian Rowe, all world renowned experts in inflammatory diseases, to its scientific advisory board (“SAB”).


These experts together with two current SAB members, Dr. John Gordon and Dr. Neil Reiner, form an advisory panel to provide input and guidance in the development of PAC-G31P. PAC-G31P is a novel peptide designed to treat inflammatory diseases characterized by non-beneficial neutrophil.

“It is an honour for Pacgen to work with this panel of experts” commented Dr. Alan Moore, Chairman of Pacgen’s Clinical Advisory Panel. “The wealth of experience and expertise of this panel will be invaluable to ensure a solid development plan is in place for PAC-G31P.”

Dr. J. Mark FitzGerald, MB, MD, FRCP(I), FRCP(C), FACCP., is the Director of the Centre for Clinical Epidemiology and Evaluation at the Vancouver Coastal Health Research Institute, and Professor and Head of the Respiratory Medicine Program at the University of British Columbia. He is a Consultant Respiratory Medicine Division at the Lung Centre, Vancouver General Hospital and a CIHR BC Lung Investigator. He is also the recipient of a Michael Smith Foundation for Health Research Distinguished Scholar Award. Dr. FitzGerald has worked with various internationally recognized groups, including the WHO and National Heart Blood and Lung Institute, USA to develop national and international asthma guidelines.

Dr. William M. Nauseef, M.D. is a Professor of Medicine and Microbiology, with additional faculty appointments in interdisciplinary programs in Immunology and Molecular & Cell Biology, and Director of the Inflammation Program at the University of Iowa. Dr. Nauseef is board-certified in both Internal Medicine and Infectious Diseases, and his research expertise is in the molecular and cell biology of human neutrophils, with special interest in myeloperoxidase and the NADPH oxidase, and he has published extensively in those areas. He serves on the editorial boards of the Journal of Biological Chemistry, Journal of Infectious Disease, and the Journal of Leukocyte Biology and is President Elect (2006) of the Society of Leukocyte Biology. His research has been funded by grants from the National Institutes of Health, the Veterans’ Administration, and the March of Dimes.

Dr. Brian H. Rowe, MD, MSc, CCFP (EM), FCCP, is an Emergency Physician at the University of Alberta Hospital in Edmonton and a Professor in the Department of Emergency Medicine at the University of Alberta. He is the Research Director of the Department of Emergency Medicine and the Co-Director of the Evidence-based Practice Center. He has been a Canada Research Chair in Emergency Airway Diseases from the government of Canada since 2001. His research interests include acute airway diseases, systematic reviews, clinical trials, and evidence-based care.



### **About Pacgen Biopharmaceuticals Corporation**

Pacgen Biopharmaceuticals Corporation is a life sciences company focused on developing peptide therapeutic drugs. The Company's current development efforts are focused on antifungal and inflammatory diseases.

PAC-113 is a novel antifungal formulated as a topical mouth rinse solution to treat oral candidiasis. A phase I/II clinical trial is underway in the United States and South Africa. This is a randomized, examiner-blinded, parallel design clinical trial with two treatment arms, PAC-113 and Nystatin oral suspension. The clinical trial intends to evaluate safety and tolerance of PAC-113 mouth rinse administered orally in HIV-positive patients, assess efficacy of PAC-113 in eliminating or reducing clinical signs and symptoms of oral candidiasis, and evaluate the microbiological response of *Candida albicans* to PAC-113.

PAC-G31P is designed to treat inflammatory diseases characterized by non-beneficial neutrophil recruitment including acute respiratory distress syndrome, asthma, pneumonia and chronic obstructive pulmonary disease. Pre-clinical toxicology studies are underway to enable an investigational new drug application or clinical trial application in North America by the end of 2007.

Pacgen is traded on the TSX Venture Exchange under the trading symbol PGA. For additional information, please visit [www.pacgenbiopharm.com](http://www.pacgenbiopharm.com).

**NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.**

### **Forward looking Statements**

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Pacgen's current beliefs as well as assumptions made by and information currently available to Pacgen and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Pacgen in its Final Prospectus dated November 28, 2006, actual events may differ materially from current expectations. Pacgen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For all forward-looking statements, Pacgen claims the safe harbour for forward-looking statements within the meaning of the Private Securities Legislation Reform.

### Contact:

Christina Yip, CMA  
Chief Financial Officer  
Pacgen Biopharmaceuticals Corporation  
Phone: 604-436-4388 ext 114  
Email: [cyip@pacgenbiopharm.com](mailto:cyip@pacgenbiopharm.com)

Fred Salari  
Manager, Investor Relations  
Pacgen Biopharmaceuticals Corporation  
Phone: 604-436-4388 ext 113  
Email: [fsalari@pacgenbiopharm.com](mailto:fsalari@pacgenbiopharm.com)